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ABSTRACT
One of the important components of the immune system, the major histocompatibility complex (MHC) molecules allow T-lymphocytes to detect cells, 
such as macrophages, B-lymphocytes, and dendritic cells that ingest infectious microorganisms or the self-cells infected with microorganism. On being 
engulfed a microorganism, macrophage partially digests it and displays peptide fragments of the microbe on its surface, bound to MHC molecules and 
the T-lymphocyte recognizes the foreign fragment attached to the MHC molecule and binds to it, lead to stimulation of an immune response. The MHC 
molecule presents peptides from its own cell (self-peptides) in healthy self-cells to which T-cells do not normally react.
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INTRODUCTION
MHCs are a class of molecules that influence the capability of an 
organism to accept or reject transplanted tissues. In contrast to the 
B-cell receptors and antibodies which recognize the antigen single 
handedly, T-cell receptor (TCR) only recognizes the antigen processed 
and presented by MHC molecules [1,2]. The functions of MHC 
molecules include its binding to a peptide fragments derived from some 
pathogenic microorganism. Display of these antigens happens on the 
cell surface for its recognition by some suitable T-cells [3]. These cause 
deleterious effects on the pathogen, virus-infected cells are killed, and 
macrophages are also induced for killing bacteria to other pathogens 
living in their intracellular vesicles [3]. Parallel to these happenings, 
B-cells are activated to generate antibodies that remove or neutralize 
extracellular pathogens [4]. In course of all these events, there are 
chances in favor of any pathogen that it has mutated in such a way so as 
to escape from presentation by an MHC molecule [5]. MHC molecules 
decide upon the response of an individual to antigenic infection. Thus, 
its role is implicated in the susceptibility to the disease as well as in 
autoimmune disease [6]. “Human leukocyte antigen” is the expanded 
version of “HLA,” which is similar to MHC in structure and function, 
is a group of antigens or proteins that are found at the surface of cells 
and in the genetic makeup or DNA [7]. A T-cell recognizes peptide 
antigen which is attached by a specific kind of allelic variant of an 
MHC molecule. It will not recognize the same peptide bound to other 
MHC molecules and this quality of T-cells is called MHC restriction [8]. 
They are the biological tools meant to identify and prevent a foreign 
protein or cell in entering or its spreading in an organism’s body [2]. 
Being one of the important components of immune system, these 
proteins recognize between self and nonself [2,3]. The MHC molecules 
are often present in vertebrates while HLA is found only in humans 
and it can be better explained as the human body’s version of MHC 
[9]. Local cells carrying viruses and other harmful organisms are often 
identified with the help of these MHC or HLA molecules and attacked 
[2]. Many times these antigenic molecules are involved when an organ 
transplant is planned for an organism or a human being. Some tests 
are carried out to determine the compatibility between an organ and 
a recipient’s body and near perfect or perfect matches are desirable 
in these situations to lessen the risk and also the chances of the 
recipient’s body in organ rejection [10]. Therefore, scope of both MHC 
and HLA in organ transplants lies in making our body and its defense 
stronger. Besides its important role in immunity, HLA is also used in 
determination of the parentage of a child by comparing antigens from 
the child, father, and mother [11] in paternity testing. Earlier studies 
have shown that these MHCs are derived from a cluster of genes and 
play an important role in both cell mediated and humoral immunity 
[2-4]. These clustered genes lie on long continuous stretch of DNA on 
the chromosome 6 among the human beings and it is on chromosome 
17 in mice [12]. In humans, they are also known by the name HLA 
complex [12]. MHC gene encodes for 3 major and important classes 
of molecules which are Class 1, 2, and 3. Class I MHC genes encode 
a particular glycoproteins on every nucleated cell of the body and 
major played by this class of molecule is the presentation of peptide 
antigens to Tc (cytotoxic T-cells) while Class II MHC genes encode 
for the glycoproteins, which are expressed only on the surface of 
antigen presenting cells (APCs) such as macrophages, dandritic cells, 
and B-cells [13]. Here, antigenic peptides after being processed are 
presented to Th-cells. Class III MHC gene encodes various proteins that 
play important immune role, and also the components of complement 
system including proteins involved in inflammation are being 
mediated by these [14]. The Class I and II molecules have important 
roles in antigen processing and presentation [13] while Class III region 
which is flanked by Class I and II regions in the gene is responsible 
for the expression of the molecules concerned with immune function 
[14]. There are number of complement factors including C2, C4, factor 
B, and several inflammatory cytokines including tumor necrosis factor 
which is expressed by the mediation of Class III MHCs [14].
MHC CLASS I MOLECULES
Structurally, MHC Class I molecules are heterodimers. It consist of 
two polypeptide chains, α and β2-microglobulin (b2m) as heavy and 
light chain, respectively [15]. The two chains are linked noncovalently 
through interaction of b2m and α3 domain. The α-chain is polymorphic 
in character and encoded by a HLA gene while the b2m subunit is not 
polymorphic and encoded by the b2m gene [15]. The α3 domain spans 
over the plasma membrane and interacts with the CD8 coreceptor of 
T-cells and this interaction holds the MHC I molecule in place [15]. The 
other kind of receptor called TCR lies on the surface of the cytotoxic 
T-cell binds its α1-α2 heterodimer ligand and checks the coupled 
peptide for antigenicity [15]. The α1 and α2 domains fold in a manner 
to make up a groove for peptides (self or nonself) to bind. MHC Class I 
molecules bind peptides that are 8-10 amino acid in length [16]. The 
peptide (self or nonself) translocation from the cytosol into the lumen 
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of the endoplasmic reticulum (ER) is accomplished by the transporter 
associated with antigen processing (TAP) which is a member of the ABC 
transporter family and is a heterodimeric multimembrane-spanning 
polypeptide consisting of TAP1 and TAP2 [15,16]. The two subunit forms 
of TAP are peptide binding site and two ATP binding sites that face the 
cytosol (Fig. 3). The antigenic or nonantigenic peptides are now bonded 
with TAP on the cytoplasmic side and translocate them by consuming 
ATPs into the lumen of the ER and then, the MHC Class I molecule is 
in turn loaded with peptides in the lumen of the ER. This complex 
phenomenon of peptide-loading involves several other molecules that 
form a large multimeric complex consisting of TAP, tapasin, calreticulin, 
calnexin, and Erp57 [16]. Calnexin acts to stabilize the Class I MHC α 
chains before β2m binding [16,17]. Following complete assembly of 
the MHC molecule, calnexin dissociates. The MHC molecule lacking a 
bound peptide is inherently unstable and requires the binding of the 
chaperones calreticulin and Erp57 [16]. The protein tapasin binds to 
the MHC molecule to link it to the TAP proteins, to facilitate enhanced 
peptide loading and colocalization.
On being loaded with the peptide, the MHC Class I molecule, the 
complex dissociates and it leaves the ER through the secretory pathway 
to reach the cell surface. The transport of the MHC Class I molecules 
through the secretory pathway involves  several posttranslational 
modifications of the MHC molecule, involving change to the N-glycan 
regions of the protein, followed by extensive changes to the N-glycans 
in the Golgi apparatus. The N-glycans’ form is the completely mature 
form before they reach the cell surface. Fig. 1 shows the processing and 
presentation of the antigen by MHC Class I molecule [17].
MHC CLASS II MOLECULES
MHC Class II consists of two polypeptide chains, α and β, each 
having two domains α1 and α2 and β1 and β2. Each chain is having a 
transmembrane domain, α2 and β2, respectively, for attaching the MHC 
Class II molecule to the cell membrane [19]. The peptide-binding groove 
is consisted of the heterodimer of α1 and β1. MHC Class II molecules 
are normally occur only on professional APCs such as macrophages, 
B-cells, and especially dendritic cells (DCs) [20]. Although they can be 
conditionally expressed by all cell types. An APC takes up an antigen, 
performs antigen processing, and returns a molecular fraction of it 
termed as the epitope to the APC’s surface, coupled within an MHC 
Class II molecule. The process is known as antigen presentation [20] 
(Fig. 4). In this unique presentation, the epitopes are recognized by 
Th-cells [19]. The CD4 receptors as well as TCRs are present on the 
surfaces of helper T-cells. When a CD4 molecule of a naive helper 
T-cell links to an APC’s MHC Class II molecule, its TCR can meet the 
epitope coupled within the MHC Class II, the phenomenon similar to 
the coupling of Tc with cytotoxic cells [19]. This event primes the naive 
helper T-cell. The varied combination of cytokines secreted by APCs in 
the microenvironment causes the naive helper T-cell to polarize into 
either a memory Th-cell or an effector Th-cell [19].
MHC Class II thus mediates immunization to APCs, differentiate the 
T-cell into memory, and effector cells so that in future if the same 
antigen invades the organism, the memory cells get activated and 
trigger the immune response [20]. The polarization during primary 
exposure to an antigen is key in determining a number of chronic 
diseases, including inflammatory bowel diseases and asthma, by 
inducing the immune response that is memory Th-cells coordinate 
when their memory recall is triggered upon secondary exposure to 
similar antigens [21].
In the phase of processing and presentation of the antigen, the 
phagocytes such as macrophages and immature dendritic cells take up 
antigenic entities by phagocytosis into phagosomes [22]. B-cells exhibit 
the more general endocytosis into endosome [23]. These phagosomes 
or endosomes fuse with lysosomes [22]. Its acidic enzymes cleave the 
uptaken protein into many different peptides. Out of these, a particular 
peptide exhibits immunodominance and loads onto MHC Class II 
molecules. APCs express both kind of MHC I & II molecules (Fig. 2). 
However, in the cell, there is highly advanced system exists to prevent 
Class II molecules from binding to same set of antigenic pepides 
as the Class I molecules [24]. In course of synthesis of MHC II in the 
ER, three pairs of Class II α β chains associate with a preassembled 
protein (trimeric) called invariant chain which interacts with peptide 
binding cleft of the MHC Class II molecules block the attachment of 
any endogenous peptide to the cleft [20]. The invariant chain complex 
with Class II molecule is now transported from the RER through golgi 
complex to endosome-lysosome assembly. During the journey from 
RER to the endosome-lysosome assembly, the invariant chain gets 
degraded under the influence of proteolytic enzymes and a small 
fragment CLIP (Class II-associated invariant chain peptide) remains 
attached to the Class II cleft [25]. For exchange of CLIP with antigenic 
Fig. 1: Antigen processing and presentation by major histocompatibility complex Class I molecule [18]
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peptide, there is requirement of nonclassical Class II molecule which 
is called HLA-DM. It is a heterodimer but not polymorphic and is not 
expressed at the cell membrane. HLA-DM is found predominantly in the 
endosomal compartment. The reaction between HLA-DM and Class II 
CLIP complex facilitates the exchange of CLIP for another peptide. 
Now, the MHC Class II molecule uploaded with the antigenic peptide is 
trafficked to and externalized on the cell surface [26].
MHC MULTIMERS
The tailormade various oligomeric forms of MHC molecules have been 
designed to identify and isolate T-cells with high affinity to specific 
antigens amid a large group of unrelated T-cells are known as MHC 
multimers. TCRs have a low affinity for their MHC counterparts. Initially, 
it was problematic to label T-cells effectively using single MHC-T-cell 
interactions. In 1996, John Altman used a complex of multiple MHC 
molecules to form a more stable bond between corresponding T-cells 
and this gave birth to the MHC multimers [27].
These multimeric molecules may range in size from dimers to 
octamers. Currently, few companies are using even higher quantities 
of MHC per multimer to increase their specificity. These molecules are 
used to display Class 1 MHC, CLASS 2 MHC, or nonclassical molecules 
such as CD1d from species such as monkeys, mice, and humans [27]. 
The most commonly used MHC multimers are tetramers which 
are typically produced by biotinylating soluble MHC monomers. 
Soluble MHC monomers are typically produced recombinantly 
in eukaryotic or bacterial cells and they then bind to a backbone, 
such as streptavidin or avidin, creating a tetravalent structure [28]. 
These backbones are conjugated with fluorochromes to isolate 
bound T-cells through flow cytometry technique. MHC multimers 
are of use in antigen-specific T-cell detection and isolation and their 
ability gives rise to several clinical applications. MHC multimers 
have broadened the strategy for ex vivo selection and proliferation 
of T-cells specific to viral or tumor-related antigens. These T-cells 
can then be reintroduced to augment the immune system. Beside 
its vast scope in T-cell selection and proliferation, MHC multimers 
can also be used to eliminate graft-originating T-cells on transplant 
organs, ex vivo and in vivo; these MHC multimers may also be used 
to eliminate harmful or unwanted T-cells, such as those that target 
self-cells and lead to autoimmune disease. We can do desirable 
modifications in cancer immunotherapy and vaccine development 
by involving MHC multimers [29].
CONCLUSION
The two major classes of MHC protein molecules are Class I and 
Class II. Class I MHC molecules span the membrane of almost every 
nucleated cell in an organism. On the other hand, class II molecules are 
concerned with cells of the immune system known as macrophages, 
dendritic cells, and lymphocytes. In human beings, these molecules are 
encoded by several genes which are clustered in the same region on 
chromosome 6 and each gene has an unusually large number of alleles 
which are actually alternate forms of a gene producing alternate forms 
of the proteins. Hence, rarely any two individual have the same type 
of set of MHC molecules, which are jointly known as tissue type. The 
MHC class III genes are so diverse and they encode for other proteins 
such as complement proteins, cytokines (chemical messengers), and 
enzymes. Besides multimer, MHC molecules have diverse scope in the 
field of clinical medicine and research. They can also be used to remove 
or arrest graft-originating T-cells due to organ transplant, ex vivo. 
In vivo, these MHC multimers may also be used to eliminate harmful or 
unwanted T-cells that lead to autoimmune disease.
Fig. 2: (a and b) Comparative account of antigen processing and 
presentation by major histocompatibility complex (MHC) Class I 
and MHC Class II molecule [18]
Fig. 3: Structure of major histocompatibility complex Class I 
molecule [18]
Fig. 4: Structure of major histocompatibility complex Class II molecule and interaction between antigen presenting cell and T-cell with its 
T-cell receptor and coreceptor CD4 [18]
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